Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection
| Autor: | Jorge Conte, Kirk Voelker, Natalia Lattanzio, Cristina Acosta-Diaz, Manuel Gordillo, Harold Vore, Zachary Kirkland, Ricardo J Villasmil, Tamela Fonseca, Karen Hamad, Roberto Mercado, James Fiorica, Angie Stewart, Sage Yenari, Caitlin Bass, Cindy Grimes, Wilhelmine Wiese-Rometsch, Mary Geary, Kevin Dawkins |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Convalescent plasma Biologic response Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) discharge to home General Engineering Infectious Disease Disease medicine.disease_cause Food and drug administration sars-cov-2 covid-19 Emergency medicine Pandemic convalescent plasma medicine Internal Medicine Public Health business skin and connective tissue diseases infusion Coronavirus |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic window for CCP administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP. Primary outcome was discharged to home/home health. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|